Document And Entity Information
Document And Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2023 | Mar. 27, 2024 | Jun. 30, 2023 | |
Document Information [Line Items] | |||
Entity Central Index Key | 0001038277 | ||
Entity Registrant Name | INTERNATIONAL ISOTOPES INC | ||
Amendment Flag | false | ||
Current Fiscal Year End Date | --12-31 | ||
Document Fiscal Period Focus | FY | ||
Document Fiscal Year Focus | 2023 | ||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Dec. 31, 2023 | ||
Document Transition Report | false | ||
Entity File Number | 000-22923 | ||
Entity Incorporation, State or Country Code | TX | ||
Entity Tax Identification Number | 74-2763837 | ||
Entity Address, Address Line One | 4137 Commerce Circle | ||
Entity Address, City or Town | Idaho Falls | ||
Entity Address, State or Province | ID | ||
Entity Address, Postal Zip Code | 83401 | ||
City Area Code | 208 | ||
Local Phone Number | 524-5300 | ||
Title of 12(g) Security | COMMON STOCK, $.01 PAR VALUE | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | false | ||
ICFR Auditor Attestation Flag | false | ||
Document Financial Statement Error Correction [Flag] | false | ||
Entity Shell Company | false | ||
Entity Public Float | $ 13,000,000 | ||
Entity Common Stock, Shares Outstanding | 520,081,365 | ||
Auditor Name | Haynie & Company | ||
Auditor Location | Salt Lake City, UT | ||
Auditor Firm ID | 457 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
Current assets | ||
Cash and cash equivalents | $ 2,688,141 | $ 2,375,817 |
Accounts receivable | 1,469,298 | 1,596,886 |
Inventories | 927,111 | 744,793 |
Prepaids and other current assets | 672,934 | 1,023,129 |
Total current assets | 5,757,484 | 5,740,625 |
Long-term assets | ||
Restricted cash | 880,752 | 840,049 |
Property, plant and equipment, net | 2,465,077 | 2,024,486 |
Capitalized lease disposal costs, net | 688,462 | 228,125 |
Financing lease right-of-use asset | 6,611 | 12,621 |
Operating lease right-of-use asset | 2,183,988 | 2,311,082 |
Goodwill | 1,384,255 | 1,384,255 |
Patents and other intangibles, net | 3,538,458 | 3,703,353 |
Total long-term assets | 11,147,603 | 10,503,971 |
Total assets | 16,905,087 | 16,244,596 |
Current liabilities | ||
Accounts payable | 559,597 | 382,392 |
Accrued liabilities | 1,482,179 | 1,472,504 |
Unearned revenue | 932,682 | 879,365 |
Current portion of operating lease right-of-use liability | 140,733 | 131,572 |
Current portion of financing lease liability | 2,832 | 5,513 |
Total current liabilities | 3,273,756 | 3,514,694 |
Long-term liabilities | ||
Accrued long-term liabilities | 75,000 | 112,500 |
Asset retirement obligation | 1,474,463 | 942,378 |
Financing lease liability, net of current portion | 0 | 2,832 |
Operating lease right-of-use liability, net of current portion | 2,091,511 | 2,232,244 |
Mandatorily redeemable convertible preferred stock | 4,063,000 | 4,063,000 |
Total long-term liabilities | 9,594,706 | 8,387,360 |
Total liabilities | 12,868,462 | 11,902,054 |
Stockholders' equity | ||
Common stock, $0.01 par value; 750,000,000 shares authorized; 519,787,870 and 514,889,916 shares issued and outstanding respectively | 5,197,879 | 5,148,899 |
Additional paid in capital | 126,168,605 | 125,654,486 |
Accumulated deficit | (127,329,859) | (126,460,843) |
Total equity | 4,036,625 | 4,342,542 |
Total liabilities and stockholders' equity | 16,905,087 | 16,244,596 |
Related Party [Member] | ||
Current liabilities | ||
Current installments of notes payable | 0 | 620,000 |
Long-term liabilities | ||
Notes payable, net of current portion | 1,620,000 | 1,000,000 |
Nonrelated Party [Member] | ||
Current liabilities | ||
Current installments of notes payable | 155,733 | 23,348 |
Long-term liabilities | ||
Notes payable, net of current portion | $ 270,732 | $ 34,406 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parentheticals) - $ / shares | Dec. 31, 2023 | Dec. 31, 2022 |
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Common stock, authorized (in shares) | 750,000,000 | 750,000,000 |
Common stock, issued (in shares) | 519,787,870 | 514,889,916 |
Common stock, outstanding (in shares) | 519,787,870 | 514,889,916 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Sale of product | $ 12,267,385 | $ 11,181,988 |
Cost of product | 4,888,409 | 4,891,927 |
Gross profit | 7,378,976 | 6,290,061 |
Operating costs and expenses: | ||
Salaries and contract labor | 4,032,155 | 3,390,652 |
General, administrative and consulting | 3,545,766 | 3,568,590 |
Research and development | 577,354 | 533,716 |
Total operating expenses | 8,155,275 | 7,492,958 |
Operating loss | (776,299) | (1,202,897) |
Other income (expense): | ||
Other income | 160,173 | 2,110,576 |
Interest income | 78,890 | 9,502 |
Interest expense | (331,780) | (613,943) |
Total other (expense) income | (92,717) | 1,506,135 |
Net income (loss) | $ (869,016) | $ 303,238 |
Net income per common share - basic: (in dollars per share) | $ 0 | $ 0 |
Net income per common share - diluted: (in dollars per share) | $ 0 | $ 0 |
Weighted average common shares outstanding - basic (in shares) | 517,777,847 | 510,794,145 |
Weighted average common shares outstanding - diluted (in shares) | 517,777,847 | 510,794,145 |
Consolidated Statement of Stock
Consolidated Statement of Stockholders' Equity - USD ($) | Series B Preferred Stock [Member] Common Stock [Member] | Series B Preferred Stock [Member] Additional Paid-in Capital [Member] | Series B Preferred Stock [Member] Retained Earnings [Member] | Series B Preferred Stock [Member] Parent [Member] | Series C Preferred Stock [Member] Common Stock [Member] | Series C Preferred Stock [Member] Additional Paid-in Capital [Member] | Series C Preferred Stock [Member] Retained Earnings [Member] | Series C Preferred Stock [Member] Parent [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Parent [Member] | Total |
Balance (in shares) | 502,584,176 | ||||||||||||
Balance (in shares) at Dec. 31, 2021 | 502,584,176 | ||||||||||||
Balance at Dec. 31, 2021 | $ 5,025,842 | $ 124,469,034 | $ (126,764,081) | $ 2,730,795 | |||||||||
Shares issued under employee stock purchase plan (in shares) | 245,081 | ||||||||||||
Shares issued under employee stock purchase plan | $ 2,451 | 12,320 | 0 | 14,771 | |||||||||
Shares issued for exercise of employee stock options (in shares) | 648,948 | 1,200,000 | |||||||||||
Shares issued for exercise of employee stock options | $ 6,489 | (6,489) | 0 | 0 | |||||||||
Stock grant (in shares) | 187,231 | ||||||||||||
Stock grant | $ 1,872 | (1,872) | 0 | 0 | |||||||||
Stock issued in lieu of dividends on preferred C shares (in shares) | 2,271,980 | ||||||||||||
Stock issued in lieu of dividends on preferred C shares | $ 22,720 | 181,760 | 0 | 204,480 | |||||||||
Warrant exercise (in shares) | 515,000 | ||||||||||||
Warrant exercise | $ 5,150 | 56,650 | 0 | 61,800 | |||||||||
Conversion of preferred B stock (in shares) | 8,437,500 | ||||||||||||
Conversion of preferred B stock | $ 84,375 | $ 590,625 | $ 0 | $ 675,000 | |||||||||
Stock based compensation | $ 0 | 352,458 | 0 | 352,458 | |||||||||
Net income (loss) | 303,238 | 303,238 | $ 303,238 | ||||||||||
Balance (in shares) at Dec. 31, 2022 | 514,889,916 | ||||||||||||
Balance at Dec. 31, 2022 | $ 5,148,899 | 125,654,486 | (126,460,843) | 4,342,542 | $ 4,342,542 | ||||||||
Balance (in shares) | 514,889,916 | ||||||||||||
Shares issued under employee stock purchase plan (in shares) | 316,866 | ||||||||||||
Shares issued under employee stock purchase plan | $ 3,169 | 5,229 | 0 | 8,398 | |||||||||
Shares issued for exercise of employee stock options (in shares) | 0 | 0 | |||||||||||
Shares issued for exercise of employee stock options | $ 0 | 0 | 0 | 0 | |||||||||
Stock grant (in shares) | 343,560 | ||||||||||||
Stock grant | $ 3,436 | (3,436) | 0 | 0 | |||||||||
Stock issued in lieu of dividends on preferred C shares (in shares) | 2,266,500 | ||||||||||||
Stock issued in lieu of dividends on preferred C shares | $ 22,665 | $ 67,995 | $ 0 | $ 90,660 | |||||||||
Stock based compensation | $ 0 | 464,041 | 0 | 464,041 | |||||||||
Net income (loss) | (869,016) | (869,016) | $ (869,016) | ||||||||||
Shares issued for issuance of RSUs (in shares) | 1,971,028 | ||||||||||||
Shares issued for issuance of RSUs | $ 19,710 | (19,710) | 0 | 0 | |||||||||
Balance (in shares) at Dec. 31, 2023 | 519,787,870 | ||||||||||||
Balance at Dec. 31, 2023 | $ 5,197,879 | $ 126,168,605 | $ (127,329,859) | $ 4,036,625 | $ 4,036,625 | ||||||||
Balance (in shares) | 519,787,870 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Cash flows from operating activities: | ||
Net income (loss) | $ (869,016) | $ 303,238 |
Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||
Depreciation and amortization | 350,094 | 374,196 |
Gain on disposal of property, plant and equipment | 0 | (1,797,978) |
Accretion of obligation for lease disposal costs | 53,126 | 50,292 |
Accretion of beneficial conversion feature | 0 | 274,443 |
Equity based compensation | 464,041 | 352,458 |
Right-of-use amortization | (4,478) | (2,528) |
Changes in operating assets and liabilities: | ||
Accounts receivable | (127,588) | 743,211 |
Prepaids and other current assets | (350,195) | 18,706 |
Inventories | 182,318 | (179,982) |
Accounts payable and accrued liabilities | 240,040 | (441,317) |
Unearned revenues | 53,317 | (28,588) |
Net cash provided by (used in) in operating activities | 582,589 | (1,497,719) |
Cash flows from investing activities: | ||
Proceeds from sale of property, plant and equipment | 0 | 4,000,000 |
Purchase of property, plant, equipment and patents | (149,058) | (120,014) |
Net cash (used in) provided by investing activities | (149,058) | 3,879,986 |
Cash flows from financing activities: | ||
Proceeds from sale of stock | 8,398 | 76,571 |
Payments on financing lease liability | (5,513) | (8,543) |
Principal payments on notes payable | (83,389) | (540,032) |
Net cash provided by (used in) financing activities | (80,504) | (472,004) |
Net increase in cash and cash equivalents and restricted cash | 353,027 | 1,910,263 |
Cash and cash equivalents and restricted cash at beginning of year | 3,215,866 | 1,305,603 |
Cash and cash equivalents and restricted cash at end of year | 3,568,893 | 3,215,866 |
Supplemental disclosure of cash flow activities: | ||
Cash paid for interest | 163,920 | 54,071 |
Cash paid for taxes | 10,176 | 9,097 |
Supplemental disclosure of noncash financing and investing transactions: | ||
Decrease in accrued interest and increase in equity for conversion preferred dividends to stock | 90,660 | 204,480 |
Increase in equity and decrease in liability for the conversion of preferred stock | 0 | 675,000 |
Property acquired in exchange for a note payable | 452,100 | 0 |
Non-cash increase of capitalized asset retirement obligation for increased funding plan | 478,959 | 0 |
Cash and cash equivalents | 2,688,141 | 2,375,817 |
Restricted cash included in long-term assets | 880,752 | 840,049 |
Total cash, cash equivalents, and restricted cash shown in statement of cash flows | $ 3,568,893 | $ 3,215,866 |
Insider Trading Arrangements
Insider Trading Arrangements | 12 Months Ended |
Dec. 31, 2023 | |
Insider Trading Arr Line Items | |
Material Terms of Trading Arrangement [Text Block] | 9B. OTHER INFORMATION During the quarter ended December 31, 2023, no 10b5 1 10b5 1 408 |
Rule 10b5-1 Arrangement Adopted [Flag] | false |
Non-Rule 10b5-1 Arrangement Adopted [Flag] | false |
Rule 10b5-1 Arrangement Terminated [Flag] | false |
Non-Rule 10b5-1 Arrangement Terminated [Flag] | false |
Note 1 - Description of Busines
Note 1 - Description of Business and Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Business Description and Accounting Policies [Text Block] | NOTE 1 Description of business November 1995. December 2010 Nature of Operations With the exception of certain unique products, the Company’s normal operating cycle is considered to be one two three not Principles of Consolidation Significant accounting policies a) Financial instruments and cash equivalents The carrying value of notes payable approximates fair value because they bear interest at rates which approximate market rates. Cash and cash equivalents, totaling $2,688,141 and $2,375,817 at December 31, 2023 2022 three At December 31, 2023 2022 The Company maintains its cash accounts in various deposit accounts, the balances of which are periodically in excess of federally insured limits. b) Accounts receivable The Company sells products mainly to recurring customers, wherein the customer’s ability to pay has previously been evaluated. The Company generally does not December 31, 2023 December 31, 2022 c) Inventories Inventories are carried at the lower of cost or net realizable value. Cost is determined using the first first December 31, 2023 December 31, 2022 d) Property, plant and equipment Depreciation on property, plant and equipment is computed using the straight-line method over the estimated useful life of the asset. Leasehold improvements are amortized over the shorter of the life of the lease or the service life of the improvements. Maintenance, repairs, and renewals that neither materially add to the value of the property nor appreciably prolong its life are charged to expense as incurred. Gains or losses on dispositions of property and equipment are included in the results of operations. e) Goodwill and other intangibles Goodwill is not December 31, 2023 2022 Patents and other intangibles are amortized using the straight-line method over their estimated useful lives and are evaluated for impairment at least annually or when events or circumstances arise that indicate the existence of impairment. The Company evaluates the recoverability of identifiable intangible assets whenever events or changes in circumstances indicate that an intangible asset’s carrying amount may not not 1 2 3 may December 31, 2023 2022 f) Impairment of long-lived assets Long-lived assets are reviewed for impairment annually, or when events or circumstances arise that indicate the existence of impairment, using the same evaluation process as described above for patents and other intangibles. There was no impairment recorded during the years ended December 31, 2023 2022 g) Income taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rate is recognized in income in the period that includes the enactment date. h) Use of estimates Management of the Company has made a number of estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses during the reporting period to prepare these consolidated financial statements in conformity with GAAP. Actual results could differ from those estimates. i) Revenue recognition Revenue is recognized when products are shipped. No 14 j) Advertising Expenses Advertising expenses, which include promotional expenses, are expensed as incurred and totaled $142,188 and $118,465 for the years ended December 31, 2023 2022 k) Research and development costs Research and development costs are expensed as incurred and totaled $577,354 and $533,716 for the years ended December 31, 2023 2022 l) Share-based compensation The Company accounts for issuances of share-based compensation to employees in accordance with GAAP which requires the recognition of the cost of employee services received in exchange for an award of equity instruments in the financial statements and is measured based on the grant date fair value of the award. Compensation expense is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period). For the years ended December 31, 2023 2022 m) Net loss per common share – basic and diluted Basic loss per share is computed on the basis of the weighted-average number of common shares outstanding during the year. Diluted loss per share is computed on the basis of the weighted-average number of common shares plus all potentially dilutive issuable common shares outstanding during the year. The table below shows the calculation of diluted shares: December 31, 2023 2022 Weighted average common shares outstanding - basic 517,777,847 510,794,145 Effects of dilutive shares Stock options — — Series C redeemable convertible preferred stock — — Weighted average common shares outstanding - diluted 517,777,847 510,794,145 For the year ended December 31, 2023 not For the year ended December 31, 2022 not The table below summarizes common stock equivalents outstanding at December 31, 2023 2022 December 31, 2023 2022 Stock options 24,787,500 24,993,500 4,063 Shares of Series C redeemable convertible preferred stock 40,630,000 40,630,000 65,417,500 65,623,500 n) Business segments and related information GAAP establishes standards for the way public business enterprises are to report information about operating segments in annual financial statements and requires enterprises to report selected information about operating segments in interim financial reports issued to shareholders. It also establishes standards for related disclosure about products and services, geographic areas and major customers. The Company currently operates in four business segments. o) Recent accounting standards In August 2020, 2020 06 470 20 815 40 December 15, 2023 |
Note 2 - Business Condition and
Note 2 - Business Condition and Liquidity | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Substantial Doubt about Going Concern [Text Block] | NOTE 2 The Company has a history of recurring losses with an accumulated deficit of $127,329,859 at December 31, 2023 2023 2023 2022 2022. During the year ended December 31, 2023 Due to changes in the nuclear industry, the Company’s plans for the design and construction of a large-scale uranium de-conversion and fluorine extraction facility were placed on hold. The Company will continue to incur some costs associated with the maintenance of licenses and other necessary project investments for the proposed facility. The Company holds a Nuclear Regulatory Commission (“NRC”) construction and operating license for the depleted uranium facility as well as the property agreement with Lea County, New Mexico, where the plant is intended to be constructed. The NRC license for the de-conversion facility is a forty first no February 2024, 12 24 The Company expects that cash from operations and its current cash balance will be sufficient to fund operations for the next twelve no |
Note 3 - Purchased Asset and In
Note 3 - Purchased Asset and Investments | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Asset Acquisition [Text Block] | NOTE 3 AMICI Asset Purchase Agreement and Medical Devices In June 2023, 510k fifth 2024. |
Note 4 - Inventories
Note 4 - Inventories | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Inventory Disclosure [Text Block] | NOTE 4 Inventories at December 31, 2023 December 31, 2022 |
Note 5 - Property, Plant and Eq
Note 5 - Property, Plant and Equipment | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Property, Plant and Equipment Disclosure [Text Block] | NOTE 5 Property, plant and equipment are summarized as follows at December 31, 2023 2022 2023 2022 Estimated Useful Lives (in years) Furniture and fixtures $ 287,463 $ 284,020 3 - 5 Transportation equipment 114,708 114,708 5 - 10 Plant and improvements 526,205 501,334 5 Production equipment 4,569,980 3,997,193 5 - 10 5,498,356 4,897,255 Accumulated depreciation (3,033,279 ) (2,872,769 ) $ 2,465,077 $ 2,024,486 Included in fixed assets are assets purchased during the planning phase for the construction of a de-conversion facility in Hobbs, New Mexico; these de-conversion facility assets are included in the DUF6 Depreciation expense was $160,567 and $185,193 for the years ended December 31, 2023 2022 |
Note 6 - Patents and Other Inta
Note 6 - Patents and Other Intangible Assets | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Intangible Assets Disclosure [Text Block] | NOTE 6 The Company owns certain patents and patents pending related to a fluorine extraction process (FEP), for various uses of some fluoride gases as fluorinating agents, and some of the RadQual nuclear medicine calibration sources. The FEP patents were developed in an effort to expand the potential markets for the high purity fluoride gases the Company had planned to produce with its fluorine extraction process. The feasibility of expanding the fluoride gas markets through the use of this patented technology is uncertain. The RadQual product patents were developed to give RadQual a unique competitive advantage by offering calibration standards exclusive to RadQual. In October 2012, 40 40 The following table summarizes the patent and intangible activity for the years ended December 31, 2023 2022 2023 Beginning $ 5,370,878 Additions — Disposals — Ending 5,370,878 Accumulated amortization (1,832,420 ) $ 3,538,458 During the year ended December 31, 2023 December 31, 2022 Patent and other intangible asset amortization is based on the remaining life of the asset and estimated amortization expense is as follows: Years ending December 31, 2025 $ 164,895 2026 164,895 2027 164,895 2028 164,895 2029 164,895 Thereafter 2,713,983 $ 3,538,458 |
Note 7 - Convertible Debentures
Note 7 - Convertible Debentures and Notes Payable | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | NOTE 7 Convertible debentures As discussed in Note 9 February 2017, two Notes payable In December 2013, one 2013 2013 June 30, 2014. 2013 may 2013 two 2013 2013 June 2014, 2013 December 31, 2017 February 2017, 2013 December 31, 2020, December 23, 2018, December 2019, 2013 December 31, 2021, January 2022, 2013 December 31, 2023, February 2024, 2013 March 31, 2026, At December 31, 2023 2013 In April 2018, 2018 2018 2018 2018 August 1, 2018. 2018 may 20 June 2018, 2018 March 31, 2019 February 2019, 2018 July 31, 2019 July 2019, 2018 January 31, 2020 December 2019, 2018 December 31, 2021 2018 December 2021, 2018 December 31, 2023 December 2023, 2018 January 31, 2025. February 2024, 2018 March 31, 2026. At December 31, 2023 2018 On December 20, 2019, four 2019 2019 December 31, 2019, 2019 February 2020, 2019 December 31, 2022. 2019 may 20 2019 January 2023, 2019 December 31, 2024, February 2024, 2019 March 31, 2026. At December 31, 2023 2019 Notes payable as of December 31, 2023 2022 2023 2022 Note payable to related parties bearing interest at 6 March 31, 2026 $ 120,000 $ 120,000 Note payable to related parties bearing interest at 4 March 31, 2026 1,000,000 1,000,000 Note payable to related parties bearing interest at 6 March 31, 2026 500,000 500,000 Note payable to a financial institution bearing interest at 5.99 1,046 34,365 44,521 Note payable for purchase contract bearing interest at 5 4,442 — 13,233 Note payable for purchase contract bearing no interest until the 25th month after the anniversary of the closing interest at 8 10,000 392,100 Total notes payable 2,046,465 1,677,754 Less: current maturities (155,733 ) (643,348 ) Notes payable, net of current installments and debt discount $ 1,890,732 $ 1,034,406 Maturities of convertible debt and notes payable, excluding debt discount and debt issuance costs, at December 31, 2023 Years ending December 31, 2024 $ 155,733 2025 124,838 2026 1,745,595 2027 20,299 Thereafter — $ 2,046,465 |
Note 8 - Lease Obligations
Note 8 - Lease Obligations | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Lessee, Operating Leases and Finance Leases [Text Block] | NOTE 8 The Company leases office and warehouse space under operating leases. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments under the lease. Operating lease, right-of-use assets, and liabilities are recognized at the lease commencement date based on the present value of lease payments over the reasonably certain lease term. The implicit rates with the Company’s operating leases are generally not may Year Ended December 31, 2023 2022 Operating lease costs $ 287,108 $ 285,159 Short-term operating lease costs 7,200 12,066 Financing lease expense: Amortization of right-of-use assets 6,023 4,172 Interest on lease liabilities 395 649 Total financing lease expense 6,418 4,821 Total lease expense $ 300,726 $ 302,046 Right-of-use assets obtained in exchange for new operating lease liabilities $ — $ — Right-of-use assets obtained in exchange for new financing lease liabilities $ — $ — Weighted-average remaining lease term (years) - operating leases 11.1 12.1 Weighted-average remaining lease term (years) - financing leases 1.2 1.1 Weighted-average discount rate - operating leases 6.75 % 6.75 % Weighted-average discount rate - financing leases 6.75 % 7.93 % Maturities of lease liabilities as of December 31, 2023 Operating leases Finance leases For the years ended December 31, 2024 $ 287,108 $ 2,929 2025 287,108 — 2026 287,108 — 2027 287,108 — 2028 287,108 — Thereafter 1,738,084 — Total minimum lease obligations 3,173,624 2,929 Less-amount representing interest (941,380 ) (97 ) Present value of minimum lease obligations 2,232,244 2,832 Current maturities (140,733 ) (2,832 ) Lease obligations, net of current maturities $ 2,091,511 $ — |
Note 9 - Shareholders' Equity,
Note 9 - Shareholders' Equity, Redeemable Convertible Preferred Stock, Options and Warrants | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Equity [Text Block] | NOTE 9 Warrants On February 14, 2022, February 17, 2022 May 12, 2022, The following table summarizes warrant activity for the years ended December 31, 2023 2022 Warrants Outstanding Shares Weighted Average Exercise Outstanding at December 31, 2021 7,065,000 $ 0.11 Granted — — Exercised (515,000 ) 0.12 Forfeited (6,550,000 ) 0.11 Outstanding at December 31, 2022 — — Granted — — Exercised — — Forfeited — — Outstanding at December 31, 2023 — $ — At December 31, 2023 December 31, 2022 Mandatorily Redeemable Convertible Preferred Stock The Company is authorized to issue up to 5,000,000 shares of preferred stock, par value $0.01 per share. The Board is authorized to set the distinguishing characteristics of each series prior to issuance, including the granting of limited or full voting rights, rights to the payment of dividends and amounts payable in event of liquidation, dissolution or winding up of the Company. At December 31, 2021, May 2022 2021, May 31, 2022, May 2022 May 31, 2022 At December 31, 2022 December 31, 2023 February 17, 2019, may February 17, 2022 February 2022, February 17, 2023. December 2022, February 17, 2025. not The Company pays dividends on the Series C Preferred Stock in February February 2023 February 2022. 2023 2022 2023 2022 The outstanding 4,063 shares of Series C Preferred Stock originated as follows: On February 17, 2017, two February 17 th February 17, 2018. The Class M Warrants were immediately exercisable at an exercise price of $0.12 per share, subject to adjustment as set forth in the warrant, and expired in February 2022. The Company allocated the proceeds to the Series C Preferred Stock and Class M Warrants based on their relative fair value, which resulted in $2,895,379 being allocated to the Series C Preferred Stock and $537,621 being allocated to the Class M Warrants. The allocated Class M Warrant value was recorded as a discount to the Series C Preferred Stock and will be amortized to interest expense over the five December 31, 2022 December 31, 2023 On March 24, 2017, July 2012 May 12, 2017, five May 12, 2017, 2021, The Class N Warrants were immediately exercisable at an exercise price of $0.10 per share, subject to adjustment as set forth in the warrant, and expired in May 2022. The Company allocated the proceeds to the Series C Preferred Stock and Class N Warrants based on their relative fair value, which resulted in $675,947 being allocated to the Series C Preferred Stock and $104,053 being allocated to the Class N Warrants. The allocated Class N Warrant value was recorded as a discount to the Series C Preferred Stock and will be amortized to interest expense over the five December 31, 2022 December 31, 2023 Employee Stock Purchase Plan In September 2004, three 423 July 2020 December 31, 2023 During 2023 2022 2015 In April 2015, 2015 “2015 July 2015. 2015 July 2018 2015 2015 2015 2006 “2006 The 2015 not 2006 2015 July 13, 2025. December 31, 2023 2015 Non-Vested Stock Grants Pursuant to an employment agreement with its Chief Executive Officer, the Company awarded 560,000 fully vested shares of common stock to its then Chief Executive Officer in February 2023 2015 20 not February 28, 2023, February 28, 2023 Pursuant to an employment agreement with its Chief Executive Officer, the Company awarded 307,692 fully vested shares of common stock to its Chief Executive Officer in February 2022 2015 20 not February 28, 2021, February 28, 2022 Stock Options A summary of the stock options issued under the Company’s equity plans is as follows: Stock Options Outstanding Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life Average Intrinsic Value Outstanding at December 31, 2021 20,777,500 0.06 627,615 Granted 8,150,000 0.09 Exercised (1,200,000 ) 0.04 57,000 Forfeited (1,734,000 ) 0.08 Outstanding at December 31, 2022 24,993,500 0.07 — Granted 3,100,000 0.04 Exercised — Forfeited (3,306,000 ) 0.08 Outstanding at December 31, 2023 24,787,500 0.05 5.4 17,000 Exercisable at December 31, 2023 19,372,500 $ 0.05 4.6 $ 16,000 The total intrinsic value of stock options outstanding at December 31, 2023 2023 The Company recognized $199,554 and $280,393 of compensation expense related to these options for the years ended December 31, 2023 2022 December 31, 2023 During the year ended December 31, 2023 In March 2022, 2015 not December 31, 2023 In August 2022, 2015 not December 31, 2023 During the year ended December 31, 2023 32 five first ten December 31, 2023 During the year ended December 31, 2022 one two five first one ten February 21, 2022, one one one one fourth one fourth ten December 31, 2022 All options exercised were issued under a qualified plan and accordingly, there is no Restricted Stock Units A summary of the non-vested restricted stock units issued under the Company’s equity plans is as follows: Non-Vested Restricted Stock Units Number of restricted stock units Weighted average grant-date fair value Outstanding at December 31, 2020 — $ — Granted — Exercised — Forfeited — Outstanding at December 31, 2021 — Granted — Vested — Forfeited / Cancelled — Outstanding at December 31, 2022 — Granted 7,250,000 0.04 Vested (250,000 ) 0.04 Forfeited / Cancelled — Outstanding at December 31, 2023 7,000,000 $ 0.04 The Company recognized $121,202 and $0 of compensation expense related to these restricted stock units ("RSU") for the years ended December 31, 2023 2022 December 31, 2023 On March 3, 2023, three On May 8, 2023, April 17, 2024, April 17, 2025, April 17, 2026. one On September 5, 2023, 2015 September 5, 2023, September 5, 2023 |
Note 10 - Income Taxes
Note 10 - Income Taxes | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | NOTE 10 The Company paid no federal or state income taxes during 2023 2022 2023 2022 Income tax expense (benefit) $ (182,493 ) $ 72,207 Book and tax differences 40,577 (72,207 ) State taxes net of federal benefit — — Change in valuation allowance 141,916 — $ — $ — The tax effects of temporary differences that give rise to significant portions of the Company’s deferred tax assets (liabilities) as of December 31, 2023 2022 2023 2022 Deferred income tax asset $ — $ — Net operating loss carryforward 7,918,996 7,736,618 Valuation allowance (7,476,180 ) (7,363,815 ) Total deferred income tax asset 442,816 372,803 Deferred income tax liability - depreciation (442,816 ) (372,803 ) Deferred tax asset (liability) $ — $ — At December 31, 2023 2024. 2023 2022 In accordance with GAAP, the Company has analyzed its filing positions in all jurisdictions where it is required to file income tax returns for the open tax years in such jurisdictions. The Company currently believes that all significant filing positions are highly certain and that all of its significant income tax filing positions and deductions would be sustained upon audit. Therefore, the Company has no significant reserves for uncertain tax positions, and no adjustment to such reserves was required by GAAP. No interest or penalties have been levied against the Company and none no The Internal Revenue Code contains provisions which reduce or limit the availability and utilization of net operating loss carry forwards in the event of a more than 50% |
Note 11 - Commitments and Conti
Note 11 - Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | NOTE 11 Dependence on Third Parties Sales during 2023 The production of Cobalt is dependent upon the DOE, and its prime operating contractor, which controls the reactor and laboratory operations at the ATR located outside of Idaho Falls, Idaho. On October 2, 2014, ten 60. October 1, 2014, September 30, 2024. may The key isotope materials used to manufacture our radiopharmaceutical product and nuclear medicine reference standards are supplied to the Company through agreements with several suppliers. The loss of any of these suppliers could adversely affect operating results by causing a delay in production or a possible loss of sales. Contingencies Because all the Company’s business segments involve the handling or use of radioactive material, the Company is required to have an operating license from the NRC and specially trained staff to handle these materials. The Company has amended this operating license numerous times to increase the amount of material permitted within the Company’s facility. Although this license does not In August 2011, no no December 31, 2014, no December 31, 2015, not 2015 December 31, 2015, December 31, 2016. not second not may, not not Defined Contribution Pension Plan The Company has a 401 “401 six 401 may 401 2022. 2023, 401 2023 401 401 |
Note 12 - Asset Retirement Obli
Note 12 - Asset Retirement Obligation | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Asset Retirement Obligation Disclosure [Text Block] | NOTE 12 As part of the Company’s NRC operating license and as part of the Company’s facility lease agreements, the Company is responsible for decommissioning any facilities upon termination or relocation of operations. The Company has developed a decommissioning funding plan using guidelines provided by the NRC and has estimated the cost of decommissioning the facility in Idaho Falls. The decommissioning cost estimate is reviewed at least annually to validate the assumptions and is revised as necessary when changes in the facility processes or radiological characteristics would affect the cost of decommissioning. In accordance with GAAP, the Company has recognized future estimated decommissioning costs as an asset retirement obligation and a related capitalized lease disposal cost. The Company has recognized period-to-period changes in the liability (accretion) in the statement of operations as amortization expense. Changes resulting from revisions to the original estimate are recorded as an increase or decrease to the capitalized lease disposal cost. Capitalized lease disposal cost is amortized on a straight-line basis over the remaining life of the facility operating lease agreement. The following summarizes the activity of the asset retirement obligation for the years ended December 31, 2023 2022 Obligation for Lease Disposal Cost Balance at December 31, 2021 892,087 Increase in lease disposal costs — Accretion expense/amortization expense 50,291 Balance at December 31, 2022 942,378 Increase in lease disposal costs 478,959 Accretion expense/amortization expense 53,126 Balance at December 31, 2023 $ 1,474,463 |
Note 13 - Fair Value Measuremen
Note 13 - Fair Value Measurements | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | NOTE 13 At December 31, 2023 2022 |
Note 14 - Revenue Recognition
Note 14 - Revenue Recognition | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Revenue from Contract with Customer [Text Block] | NOTE 14 Revenue from Product Sales The following tables present the Company’s revenue disaggregated by business segment and geography, based on management’s assessment of available data: Twelve Months Ended December 31, 2023 Twelve Months Ended December 31, 2022 U.S. Outside U.S. Total Revenues % of Total Revenues U.S. Outside U.S. Total Revenues % of Total Revenues Theranostics Products $ 5,685,244 $ 1,157,654 $ 6,842,898 56 % $ 5,338,010 $ 707,757 $ 6,045,767 54 % Cobalt Products 932,915 104,158 1,037,073 8 % 1,137,066 20,470 1,157,536 10 % Nuclear Medicine Products 3,405,508 981,906 4,387,414 36 % 3,173,755 804,930 3,978,685 36 % Fluorine Products — — — 0 % — — — 0 % $ 10,023,667 $ 2,243,718 $ 12,267,385 100 % $ 9,648,831 $ 1,533,157 $ 11,181,988 100 % Prior period amounts have not Under ASC Topic 606, Product sales consist of a single performance obligation that the Company satisfies at a point in time. All transactions in the Theranostics Products and nuclear medicine standards segments fall into this category. Most sales transactions in the cobalt products business segment fall into this category but other cobalt product sales are recorded as deferred income as discussed below. The Company recognizes product revenue when the following events have occurred: (a) the Company has transferred physical possession of the products, (b) the Company has a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. Based on the Company’s historical practices and shipping terms specified in the sales agreements and invoices, these criteria are generally met when the products are: • Invoiced. • Shipped from the Company’s facilities (“FOB shipping point”, which is the Company’s standard shipping term). For these sales, the Company determined that the customer is able to direct the use of, and obtain substantially all of the benefits from, the products at the time the products are shipped. The Company’s revenue consists primarily of products manufactured for use in the nuclear medicine industry, distribution of radiochemicals and radiopharmaceuticals, and cobalt source manufacturing. With the exception of certain unique products, the Company’s normal operating cycle is considered to be one two three not one December 31, 2023 December 31, 2022 Contract Balances The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of December 31, 2023 December 31, 2022 Practical Expedients The Company has elected the practical expedient not |
Note 15 - Segment Information
Note 15 - Segment Information | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Segment Reporting Disclosure [Text Block] | NOTE 15 Information related to the Company’s reportable operating business segments is shown below. The Company’s reportable segments are reported in a manner consistent with the way management evaluates the businesses. The Company identifies its reportable business segments based on differences in products and services. The accounting policies of the business segments are the same as those described in the summary of significant accounting policies. The Company has identified the following business segments: ● The Nuclear Medicine Standards segment consists of the manufacture of sources and standards associated with Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) imaging, patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy industry and includes consolidated reporting of the wholly-owned subsidiaries RadQual and TI Services. ● The Cobalt Products segment includes management of a cobalt irradiation contract, fabrication of cobalt capsules for teletherapy or irradiation devices, and recycling of expended cobalt sources. ● The Theranostics Products Segment (formerly called the Radiochemical Products Segment) includes production and distribution of Iodine- 131 131 ● The Fluorine Products segment historically involved the production of small-scale qualification samples of high purity fluoride gas for various industrial applications, as well as development of laboratory and analytical processes required to support the planned uranium de-conversion and fluorine extraction facility. During 2013, The following presents certain segment information as of and for the years ended December 31, 2023 2022 Sale of product 2023 2022 Theranostics products $ 6,842,898 $ 6,045,767 Cobalt products 1,037,073 1,157,536 Nuclear medicine standards 4,387,414 3,978,685 Fluorine products — — Total segments 12,267,385 11,181,988 Corporate revenue — — Total consolidated $ 12,267,385 $ 11,181,988 Depreciation and amortization 2023 2022 Theranostics products $ 25,287 $ 63,493 Cobalt products 53,331 49,202 Nuclear medicine standards 114,833 114,990 Fluorine products 115,879 115,598 Total segments 309,330 343,283 Corporate depreciation and amortization 40,764 30,913 Total consolidated $ 350,094 $ 374,196 Segment income (loss) 2023 2022 Theranostics products $ 3,037,375 $ 4,182,151 Cobalt products (126,504 ) (95,779 ) Nuclear medicine standards 386,592 39,223 Fluorine products (105,099 ) (139,860 ) Total segments 3,192,364 3,985,735 Corporate loss (4,061,380 ) (3,682,497 ) Total consolidated $ (869,016 ) $ 303,238 Expenditures for segment assets 2023 2022 Theranostics products $ 3,420 $ 3,379 Cobalt products 49,774 17,105 Nuclear medicine standards 35,137 75,478 Fluorine products — 4,100 Total segments 88,331 100,062 Corporate purchases 60,727 19,952 Total consolidated $ 149,058 $ 120,014 Segment assets 2023 2022 Theranostics products $ 849,351 $ 1,075,252 Cobalt products 274,513 406,629 Nuclear medicine standards 3,538,558 2,744,394 Fluorine products 4,980,118 5,147,325 Total segments 9,642,540 9,373,600 Corporate assets 7,262,547 6,870,996 Total consolidated $ 16,905,087 $ 16,244,596 |
Note 16 - Subsequent Events
Note 16 - Subsequent Events | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | NOTE 16 On February 8, 2024, 6 12 24 The purchase price to be paid by AFR in the Acquisition will consist of (i) $50,000 to be paid within five 6 6 The APA may not March 31, 2026. In February 2024, 2013 March 31, 2026, In February 2024, 2018 March 31, 2026, In February 2024, 2019 March 31, 2026, |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Fair Value of Financial Instruments, Policy [Policy Text Block] | a) Financial instruments and cash equivalents The carrying value of notes payable approximates fair value because they bear interest at rates which approximate market rates. Cash and cash equivalents, totaling $2,688,141 and $2,375,817 at December 31, 2023 2022 three At December 31, 2023 2022 The Company maintains its cash accounts in various deposit accounts, the balances of which are periodically in excess of federally insured limits. |
Receivable [Policy Text Block] | b) Accounts receivable The Company sells products mainly to recurring customers, wherein the customer’s ability to pay has previously been evaluated. The Company generally does not December 31, 2023 December 31, 2022 |
Inventory, Policy [Policy Text Block] | c) Inventories Inventories are carried at the lower of cost or net realizable value. Cost is determined using the first first December 31, 2023 December 31, 2022 |
Property, Plant and Equipment, Policy [Policy Text Block] | d) Property, plant and equipment Depreciation on property, plant and equipment is computed using the straight-line method over the estimated useful life of the asset. Leasehold improvements are amortized over the shorter of the life of the lease or the service life of the improvements. Maintenance, repairs, and renewals that neither materially add to the value of the property nor appreciably prolong its life are charged to expense as incurred. Gains or losses on dispositions of property and equipment are included in the results of operations. |
Goodwill and Intangible Assets, Policy [Policy Text Block] | e) Goodwill and other intangibles Goodwill is not December 31, 2023 2022 Patents and other intangibles are amortized using the straight-line method over their estimated useful lives and are evaluated for impairment at least annually or when events or circumstances arise that indicate the existence of impairment. The Company evaluates the recoverability of identifiable intangible assets whenever events or changes in circumstances indicate that an intangible asset’s carrying amount may not not 1 2 3 may December 31, 2023 2022 |
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] | f) Impairment of long-lived assets Long-lived assets are reviewed for impairment annually, or when events or circumstances arise that indicate the existence of impairment, using the same evaluation process as described above for patents and other intangibles. There was no impairment recorded during the years ended December 31, 2023 2022 |
Income Tax, Policy [Policy Text Block] | g) Income taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rate is recognized in income in the period that includes the enactment date. |
Use of Estimates, Policy [Policy Text Block] | h) Use of estimates Management of the Company has made a number of estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses during the reporting period to prepare these consolidated financial statements in conformity with GAAP. Actual results could differ from those estimates. |
Revenue [Policy Text Block] | i) Revenue recognition Revenue is recognized when products are shipped. No 14 |
Advertising Cost [Policy Text Block] | j) Advertising Expenses Advertising expenses, which include promotional expenses, are expensed as incurred and totaled $142,188 and $118,465 for the years ended December 31, 2023 2022 |
Research and Development Expense, Policy [Policy Text Block] | k) Research and development costs Research and development costs are expensed as incurred and totaled $577,354 and $533,716 for the years ended December 31, 2023 2022 |
Share-Based Payment Arrangement [Policy Text Block] | l) Share-based compensation The Company accounts for issuances of share-based compensation to employees in accordance with GAAP which requires the recognition of the cost of employee services received in exchange for an award of equity instruments in the financial statements and is measured based on the grant date fair value of the award. Compensation expense is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period). For the years ended December 31, 2023 2022 |
Earnings Per Share, Policy [Policy Text Block] | m) Net loss per common share – basic and diluted Basic loss per share is computed on the basis of the weighted-average number of common shares outstanding during the year. Diluted loss per share is computed on the basis of the weighted-average number of common shares plus all potentially dilutive issuable common shares outstanding during the year. The table below shows the calculation of diluted shares: December 31, 2023 2022 Weighted average common shares outstanding - basic 517,777,847 510,794,145 Effects of dilutive shares Stock options — — Series C redeemable convertible preferred stock — — Weighted average common shares outstanding - diluted 517,777,847 510,794,145 For the year ended December 31, 2023 not For the year ended December 31, 2022 not The table below summarizes common stock equivalents outstanding at December 31, 2023 2022 December 31, 2023 2022 Stock options 24,787,500 24,993,500 4,063 Shares of Series C redeemable convertible preferred stock 40,630,000 40,630,000 65,417,500 65,623,500 |
Segment Reporting, Policy [Policy Text Block] | n) Business segments and related information GAAP establishes standards for the way public business enterprises are to report information about operating segments in annual financial statements and requires enterprises to report selected information about operating segments in interim financial reports issued to shareholders. It also establishes standards for related disclosure about products and services, geographic areas and major customers. The Company currently operates in four business segments. |
New Accounting Pronouncements, Policy [Policy Text Block] | o) Recent accounting standards In August 2020, 2020 06 470 20 815 40 December 15, 2023 |
Note 1 - Description of Busin_2
Note 1 - Description of Business and Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Schedule of Weighted Average Number of Shares [Table Text Block] | December 31, 2023 2022 Weighted average common shares outstanding - basic 517,777,847 510,794,145 Effects of dilutive shares Stock options — — Series C redeemable convertible preferred stock — — Weighted average common shares outstanding - diluted 517,777,847 510,794,145 |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | December 31, 2023 2022 Stock options 24,787,500 24,993,500 4,063 Shares of Series C redeemable convertible preferred stock 40,630,000 40,630,000 65,417,500 65,623,500 |
Note 5 - Property, Plant and _2
Note 5 - Property, Plant and Equipment (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | 2023 2022 Estimated Useful Lives (in years) Furniture and fixtures $ 287,463 $ 284,020 3 - 5 Transportation equipment 114,708 114,708 5 - 10 Plant and improvements 526,205 501,334 5 Production equipment 4,569,980 3,997,193 5 - 10 5,498,356 4,897,255 Accumulated depreciation (3,033,279 ) (2,872,769 ) $ 2,465,077 $ 2,024,486 |
Note 6 - Patents and Other In_2
Note 6 - Patents and Other Intangible Assets (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Schedule of Finite-Lived Intangible Assets [Table Text Block] | 2023 Beginning $ 5,370,878 Additions — Disposals — Ending 5,370,878 Accumulated amortization (1,832,420 ) $ 3,538,458 |
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] | Years ending December 31, 2025 $ 164,895 2026 164,895 2027 164,895 2028 164,895 2029 164,895 Thereafter 2,713,983 $ 3,538,458 |
Note 7 - Convertible Debentur_2
Note 7 - Convertible Debentures and Notes Payable (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Schedule of Long-Term Debt Instruments [Table Text Block] | 2023 2022 Note payable to related parties bearing interest at 6 March 31, 2026 $ 120,000 $ 120,000 Note payable to related parties bearing interest at 4 March 31, 2026 1,000,000 1,000,000 Note payable to related parties bearing interest at 6 March 31, 2026 500,000 500,000 Note payable to a financial institution bearing interest at 5.99 1,046 34,365 44,521 Note payable for purchase contract bearing interest at 5 4,442 — 13,233 Note payable for purchase contract bearing no interest until the 25th month after the anniversary of the closing interest at 8 10,000 392,100 Total notes payable 2,046,465 1,677,754 Less: current maturities (155,733 ) (643,348 ) Notes payable, net of current installments and debt discount $ 1,890,732 $ 1,034,406 |
Schedule of Maturities of Long-Term Debt [Table Text Block] | Years ending December 31, 2024 $ 155,733 2025 124,838 2026 1,745,595 2027 20,299 Thereafter — $ 2,046,465 |
Note 8 - Lease Obligations (Tab
Note 8 - Lease Obligations (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Lease, Cost [Table Text Block] | Year Ended December 31, 2023 2022 Operating lease costs $ 287,108 $ 285,159 Short-term operating lease costs 7,200 12,066 Financing lease expense: Amortization of right-of-use assets 6,023 4,172 Interest on lease liabilities 395 649 Total financing lease expense 6,418 4,821 Total lease expense $ 300,726 $ 302,046 Right-of-use assets obtained in exchange for new operating lease liabilities $ — $ — Right-of-use assets obtained in exchange for new financing lease liabilities $ — $ — Weighted-average remaining lease term (years) - operating leases 11.1 12.1 Weighted-average remaining lease term (years) - financing leases 1.2 1.1 Weighted-average discount rate - operating leases 6.75 % 6.75 % Weighted-average discount rate - financing leases 6.75 % 7.93 % |
Lessee, Liability, to be Paid, Maturity [ Table Text Block] | Operating leases Finance leases For the years ended December 31, 2024 $ 287,108 $ 2,929 2025 287,108 — 2026 287,108 — 2027 287,108 — 2028 287,108 — Thereafter 1,738,084 — Total minimum lease obligations 3,173,624 2,929 Less-amount representing interest (941,380 ) (97 ) Present value of minimum lease obligations 2,232,244 2,832 Current maturities (140,733 ) (2,832 ) Lease obligations, net of current maturities $ 2,091,511 $ — |
Note 9 - Shareholders' Equity_2
Note 9 - Shareholders' Equity, Redeemable Convertible Preferred Stock, Options and Warrants (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Warrants Outstanding Shares Weighted Average Exercise Outstanding at December 31, 2021 7,065,000 $ 0.11 Granted — — Exercised (515,000 ) 0.12 Forfeited (6,550,000 ) 0.11 Outstanding at December 31, 2022 — — Granted — — Exercised — — Forfeited — — Outstanding at December 31, 2023 — $ — |
Share-Based Payment Arrangement, Option, Activity [Table Text Block] | Stock Options Outstanding Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life Average Intrinsic Value Outstanding at December 31, 2021 20,777,500 0.06 627,615 Granted 8,150,000 0.09 Exercised (1,200,000 ) 0.04 57,000 Forfeited (1,734,000 ) 0.08 Outstanding at December 31, 2022 24,993,500 0.07 — Granted 3,100,000 0.04 Exercised — Forfeited (3,306,000 ) 0.08 Outstanding at December 31, 2023 24,787,500 0.05 5.4 17,000 Exercisable at December 31, 2023 19,372,500 $ 0.05 4.6 $ 16,000 |
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] | Non-Vested Restricted Stock Units Number of restricted stock units Weighted average grant-date fair value Outstanding at December 31, 2020 — $ — Granted — Exercised — Forfeited — Outstanding at December 31, 2021 — Granted — Vested — Forfeited / Cancelled — Outstanding at December 31, 2022 — Granted 7,250,000 0.04 Vested (250,000 ) 0.04 Forfeited / Cancelled — Outstanding at December 31, 2023 7,000,000 $ 0.04 |
Note 10 - Income Taxes (Tables)
Note 10 - Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | 2023 2022 Income tax expense (benefit) $ (182,493 ) $ 72,207 Book and tax differences 40,577 (72,207 ) State taxes net of federal benefit — — Change in valuation allowance 141,916 — $ — $ — |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | 2023 2022 Deferred income tax asset $ — $ — Net operating loss carryforward 7,918,996 7,736,618 Valuation allowance (7,476,180 ) (7,363,815 ) Total deferred income tax asset 442,816 372,803 Deferred income tax liability - depreciation (442,816 ) (372,803 ) Deferred tax asset (liability) $ — $ — |
Note 12 - Asset Retirement Ob_2
Note 12 - Asset Retirement Obligation (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Schedule of Change in Asset Retirement Obligation [Table Text Block] | Obligation for Lease Disposal Cost Balance at December 31, 2021 892,087 Increase in lease disposal costs — Accretion expense/amortization expense 50,291 Balance at December 31, 2022 942,378 Increase in lease disposal costs 478,959 Accretion expense/amortization expense 53,126 Balance at December 31, 2023 $ 1,474,463 |
Note 14 - Revenue Recognition (
Note 14 - Revenue Recognition (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Disaggregation of Revenue [Table Text Block] | Twelve Months Ended December 31, 2023 Twelve Months Ended December 31, 2022 U.S. Outside U.S. Total Revenues % of Total Revenues U.S. Outside U.S. Total Revenues % of Total Revenues Theranostics Products $ 5,685,244 $ 1,157,654 $ 6,842,898 56 % $ 5,338,010 $ 707,757 $ 6,045,767 54 % Cobalt Products 932,915 104,158 1,037,073 8 % 1,137,066 20,470 1,157,536 10 % Nuclear Medicine Products 3,405,508 981,906 4,387,414 36 % 3,173,755 804,930 3,978,685 36 % Fluorine Products — — — 0 % — — — 0 % $ 10,023,667 $ 2,243,718 $ 12,267,385 100 % $ 9,648,831 $ 1,533,157 $ 11,181,988 100 % |
Note 15 - Segment Information (
Note 15 - Segment Information (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Schedule of Segment Reporting Information, by Segment [Table Text Block] | Sale of product 2023 2022 Theranostics products $ 6,842,898 $ 6,045,767 Cobalt products 1,037,073 1,157,536 Nuclear medicine standards 4,387,414 3,978,685 Fluorine products — — Total segments 12,267,385 11,181,988 Corporate revenue — — Total consolidated $ 12,267,385 $ 11,181,988 Depreciation and amortization 2023 2022 Theranostics products $ 25,287 $ 63,493 Cobalt products 53,331 49,202 Nuclear medicine standards 114,833 114,990 Fluorine products 115,879 115,598 Total segments 309,330 343,283 Corporate depreciation and amortization 40,764 30,913 Total consolidated $ 350,094 $ 374,196 Segment income (loss) 2023 2022 Theranostics products $ 3,037,375 $ 4,182,151 Cobalt products (126,504 ) (95,779 ) Nuclear medicine standards 386,592 39,223 Fluorine products (105,099 ) (139,860 ) Total segments 3,192,364 3,985,735 Corporate loss (4,061,380 ) (3,682,497 ) Total consolidated $ (869,016 ) $ 303,238 Expenditures for segment assets 2023 2022 Theranostics products $ 3,420 $ 3,379 Cobalt products 49,774 17,105 Nuclear medicine standards 35,137 75,478 Fluorine products — 4,100 Total segments 88,331 100,062 Corporate purchases 60,727 19,952 Total consolidated $ 149,058 $ 120,014 Segment assets 2023 2022 Theranostics products $ 849,351 $ 1,075,252 Cobalt products 274,513 406,629 Nuclear medicine standards 3,538,558 2,744,394 Fluorine products 4,980,118 5,147,325 Total segments 9,642,540 9,373,600 Corporate assets 7,262,547 6,870,996 Total consolidated $ 16,905,087 $ 16,244,596 |
Note 1 - Description of Busin_3
Note 1 - Description of Business and Significant Accounting Policies (Details Textual) | 12 Months Ended | |
Dec. 31, 2023 USD ($) shares | Dec. 31, 2022 USD ($) shares | |
Number of Operating Segments | 4 | |
Cash and Cash Equivalents, at Carrying Value | $ 2,688,141 | $ 2,375,817 |
Accounts Receivable, Allowance for Credit Loss, Current | 0 | 0 |
Inventory Write-down | 0 | 0 |
Goodwill, Impairment Loss | 0 | 0 |
Impairment of Intangible Assets, Finite-Lived | 0 | 0 |
Impairment, Long-Lived Asset, Held-for-Use | 0 | 0 |
Advertising Expense | 142,188 | 118,465 |
Research and Development Expense | 577,354 | 533,716 |
Share-Based Payment Arrangement, Expense | $ 464,041 | $ 352,458 |
Share-Based Payment Arrangement, Option [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares | 24,787,500 | 24,993,500 |
Series C Preferred Stock [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares | 4,063,000 | 4,063,000 |
Asset Pledged as Collateral [Member] | Surety Bond [Member] | ||
Money Market Funds, at Carrying Value | $ 880,752 | $ 840,049 |
Note 1 - Description of Busin_4
Note 1 - Description of Business and Significant Accounting Policies - Schedule of Weighted Average Number of Shares (Details) - shares | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Weighted average common shares outstanding - basic (in shares) | 517,777,847 | 510,794,145 |
Stock options (in shares) | 0 | 0 |
Series C redeemable convertible preferred stock (in shares) | 0 | 0 |
Weighted average common shares outstanding - diluted (in shares) | 517,777,847 | 510,794,145 |
Note 1 - Description of Busin_5
Note 1 - Description of Business and Significant Accounting Policies - Schedule of Common Stock Equivalents Outstanding (Details) - shares | Dec. 31, 2023 | Dec. 31, 2022 |
Common stock equivalents (in shares) | 65,417,500 | 65,623,500 |
Series C Preferred Stock [Member] | ||
Common stock equivalents (in shares) | 40,630,000 | 40,630,000 |
Share-Based Payment Arrangement, Option [Member] | ||
Common stock equivalents (in shares) | 24,787,500 | 24,993,500 |
Note 2 - Business Condition a_2
Note 2 - Business Condition and Liquidity (Details Textual) - USD ($) | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2025 | |
Retained Earnings (Accumulated Deficit) | $ (127,329,859) | $ (126,460,843) | |
Net Income (Loss) Attributable to Parent | (869,016) | 303,238 | |
Increase (Decrease) in Operating Capital | 257,797 | ||
Net Cash Provided by (Used in) Operating Activities | 582,589 | (1,497,719) | |
Increase (Decrease) in Net Income (Loss) | (1,172,254) | ||
Gain (Loss) on Disposition of Property Plant Equipment | $ 0 | $ 1,797,978 | |
Discontinued Operations, Held-for-Sale or Disposed of by Sale [Member] | Assets Associated With Planned De-conversion Facility [Member] | Forecast [Member] | |||
Disposal Group, Including Discontinued Operation, Consideration | $ 12,500,000 | ||
NRC License for the De-conversion Facility [Member] | |||
License Term (Year) | 40 years |
Note 4 - Inventories (Details T
Note 4 - Inventories (Details Textual) - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
Inventory, Net | $ 927,111 | $ 744,793 |
Note 5 - Property, Plant and _3
Note 5 - Property, Plant and Equipment (Details Textual) - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Depreciation | $ 160,567 | $ 185,193 |
Note 5 - Property, Plant and _4
Note 5 - Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details) - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
Property, Plant and Equipment, gross | $ 5,498,356 | $ 4,897,255 |
Accumulated depreciation | (3,033,279) | (2,872,769) |
Property, Plant and Equipment, net | 2,465,077 | 2,024,486 |
Furniture and Fixtures [Member] | ||
Property, Plant and Equipment, gross | $ 287,463 | 284,020 |
Furniture and Fixtures [Member] | Minimum [Member] | ||
Property, Plant and Equipment, useful life (Year) | 3 years | |
Furniture and Fixtures [Member] | Maximum [Member] | ||
Property, Plant and Equipment, useful life (Year) | 5 years | |
Transportation Equipment [Member] | ||
Property, Plant and Equipment, gross | $ 114,708 | 114,708 |
Transportation Equipment [Member] | Minimum [Member] | ||
Property, Plant and Equipment, useful life (Year) | 5 years | |
Transportation Equipment [Member] | Maximum [Member] | ||
Property, Plant and Equipment, useful life (Year) | 10 years | |
Building [Member] | ||
Property, Plant and Equipment, gross | $ 526,205 | 501,334 |
Property, Plant and Equipment, useful life (Year) | 5 years | |
Production Equipment [Member] | ||
Property, Plant and Equipment, gross | $ 4,569,980 | $ 3,997,193 |
Production Equipment [Member] | Minimum [Member] | ||
Property, Plant and Equipment, useful life (Year) | 5 years | |
Production Equipment [Member] | Maximum [Member] | ||
Property, Plant and Equipment, useful life (Year) | 10 years |
Note 6 - Patents and Other In_3
Note 6 - Patents and Other Intangible Assets (Details Textual) - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Amortization of Intangible Assets | $ 164,895 | $ 164,370 |
Note 6 - Patents and Other In_4
Note 6 - Patents and Other Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Beginning | $ 5,370,878 | |
Additions | 0 | |
Disposals | 0 | $ 0 |
Ending | 5,370,878 | 5,370,878 |
Accumulated amortization | (1,832,420) | |
Finite-Lived Intangible Assets, Net | $ 3,538,458 | $ 3,703,353 |
Note 6 - Patents and Other In_5
Note 6 - Patents and Other Intangible Assets - Schedule of Future Amortization Expense (Details) - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
2025 | $ 164,895 | |
2026 | 164,895 | |
2027 | 164,895 | |
2028 | 164,895 | |
2029 | 164,895 | |
Thereafter | 2,713,983 | |
Finite-Lived Intangible Assets, Net | $ 3,538,458 | $ 3,703,353 |
Note 7 - Convertible Debentur_3
Note 7 - Convertible Debentures and Notes Payable (Details Textual) - USD ($) | 1 Months Ended | |||||||||||
Dec. 31, 2019 | Dec. 23, 2018 | May 12, 2017 | Feb. 29, 2020 | Apr. 30, 2018 | Feb. 28, 2017 | Dec. 31, 2013 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 20, 2019 | Jun. 30, 2014 | |
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0 | $ 0 | $ 0.11 | |||||||||
Class of Warrant or Right, Outstanding (in shares) | 0 | 0 | 7,065,000 | |||||||||
Class L Warrants [Member] | ||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 5,000,000 | 7,500,000 | ||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.06 | $ 0.06 | ||||||||||
Warrants and Rights Outstanding | $ 384,428 | |||||||||||
Class of Warrants or Rights, Expirations (in shares) | 25,000,000 | |||||||||||
Class O Warrants [Member] | ||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.045 | |||||||||||
Class of Warrant or Right, Outstanding (in shares) | 30,000,000 | |||||||||||
The 2013 Promissory Note [Member] | Major Shareholders [Member] | ||||||||||||
Proceeds from Related Party Debt | $ 500,000 | |||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 6% | |||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 15,464 | |||||||||||
Interest Payable | $ 301,734 | |||||||||||
The 2018 Promissory Note [Member] | Chief Executive Officer and Chairman of the Board [Member] | ||||||||||||
Proceeds from Related Party Debt | $ 120,000 | |||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 6% | |||||||||||
Interest Payable | 40,970 | |||||||||||
The 2019 Promissory Note [Member] | Major Shareholders [Member] | ||||||||||||
Proceeds from Related Party Debt | $ 675,000 | $ 325,000 | ||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 4% | |||||||||||
Interest Payable | $ 159,131 | |||||||||||
Debt Instrument, Face Amount | $ 1,000,000 | |||||||||||
Conversion of Convertible Debentures Into Series C Preferred Stock and Warrants [Member] | ||||||||||||
Debt Conversion, Original Debt, Amount | $ 780,000 | $ 205,000 | ||||||||||
Private Placement [Member] | Series C Preferred Stock [Member] | ||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 3,433 |
Note 7 - Convertible Debentur_4
Note 7 - Convertible Debentures and Notes Payable - Schedule of Long-term Debt Instruments (Details) - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
Notes payable | $ 2,046,465 | $ 1,677,754 |
Less: current maturities | (155,733) | (643,348) |
Notes payable, net of current installments and debt discount | 1,890,732 | 1,034,406 |
Notes Payable, Other Payables [Member] | Related Party One [Member] | ||
Notes payable | 120,000 | 120,000 |
Notes Payable, Other Payables [Member] | Related Party Two [Member] | ||
Notes payable | 1,000,000 | 1,000,000 |
Notes Payable, Other Payables [Member] | Related Party Three [Member] | ||
Notes payable | 500,000 | 500,000 |
Notes Payable to Banks [Member] | ||
Notes payable | 34,365 | 44,521 |
Notes Payable for Purchase Contract, One [Member] | ||
Notes payable | 0 | 13,233 |
Notes Payable for Purchase Contract, Two [Member] | ||
Notes payable | $ 392,100 |
Note 7 - Convertible Debentur_5
Note 7 - Convertible Debentures and Notes Payable - Schedule of Long-term Debt Instruments (Details) (Parentheticals) - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Notes Payable, Other Payables [Member] | Related Party One [Member] | ||
Stated interest rate | 6% | 6% |
Maturity date | Mar. 31, 2026 | Mar. 31, 2026 |
Notes Payable, Other Payables [Member] | Related Party Two [Member] | ||
Stated interest rate | 4% | 4% |
Maturity date | Mar. 31, 2026 | Mar. 31, 2026 |
Notes Payable, Other Payables [Member] | Related Party Three [Member] | ||
Stated interest rate | 6% | 6% |
Maturity date | Mar. 31, 2026 | Mar. 31, 2026 |
Notes Payable to Banks [Member] | ||
Stated interest rate | 5.99% | 5.99% |
Periodic payments | $ 1,046 | $ 1,046 |
Notes Payable for Purchase Contract, One [Member] | ||
Stated interest rate | 5% | |
Periodic payments | $ 4,442 | |
Notes Payable for Purchase Contract, Two [Member] | ||
Stated interest rate | 8% | |
Periodic payments | $ 10,000 |
Note 7 - Convertible Debentur_6
Note 7 - Convertible Debentures and Notes Payable - Schedule of Maturities of Long-term Debt (Details) | Dec. 31, 2023 USD ($) |
2024 | $ 155,733 |
2025 | 124,838 |
2026 | 1,745,595 |
2027 | 20,299 |
Thereafter | 0 |
Long-Term Debt | $ 2,046,465 |
Note 8 - Lease Obligations - Le
Note 8 - Lease Obligations - Lease Cost (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Operating lease costs | $ 287,108 | $ 285,159 |
Short-term operating lease costs | 7,200 | 12,066 |
Amortization of right-of-use assets | 6,023 | 4,172 |
Interest on lease liabilities | 395 | 649 |
Total financing lease expense | 6,418 | 4,821 |
Total lease expense | 300,726 | 302,046 |
Right-of-use assets obtained in exchange for new operating lease liabilities | 0 | 0 |
Right-of-use assets obtained in exchange for new financing lease liabilities | $ 0 | $ 0 |
Weighted-average remaining lease term (years) - operating leases (Year) | 11 years 1 month 6 days | 12 years 1 month 6 days |
Weighted-average remaining lease term (years) - financing leases (Year) | 1 year 2 months 12 days | 1 year 1 month 6 days |
Weighted-average discount rate - operating leases | 6.75% | 6.75% |
Weighted-average discount rate - financing leases | 6.75% | 7.93% |
Note 8 - Lease Obligations - Sc
Note 8 - Lease Obligations - Schedule of Future Minimum Lease Payments (Details) - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
Operating lease, 2024 | $ 287,108 | |
Finance lease, 2024 | 2,929 | |
Operating lease, 2025 | 287,108 | |
Finance lease, 2025 | 0 | |
Operating lease, 2026 | 287,108 | |
Finance lease, 2026 | 0 | |
Operating lease, 2027 | 287,108 | |
Finance lease, 2027 | 0 | |
Operating lease, 2028 | 287,108 | |
Finance lease, 2028 | 0 | |
Operating lease, Thereafter | 1,738,084 | |
Finance lease, Thereafter | 0 | |
Total minimum operating lease obligations | 3,173,624 | |
Total minimum finance lease obligations | 2,929 | |
Less-amount representing interest, operating lease | (941,380) | |
Less-amount representing interest, finance lease | (97) | |
Present value of minimum operating lease obligations | 2,232,244 | |
Present value of minimum finance lease obligations | 2,832 | |
Current operating lease maturities | (140,733) | $ (131,572) |
Current finance lease maturities | (2,832) | (5,513) |
Operating lease obligations, net of current maturities | 2,091,511 | 2,232,244 |
Finance lease obligations, net of current maturities | $ 0 | $ 2,832 |
Note 9 - Shareholders' Equity_3
Note 9 - Shareholders' Equity, Redeemable Convertible Preferred Stock, Options and Warrants (Details Textual) | 1 Months Ended | 12 Months Ended | ||||||||||||||||||||
Sep. 05, 2023 USD ($) $ / shares shares | May 08, 2023 shares | Mar. 03, 2023 shares | Feb. 28, 2023 USD ($) $ / shares shares | May 31, 2022 USD ($) $ / shares shares | May 12, 2022 shares | Feb. 28, 2022 USD ($) $ / shares shares | Feb. 17, 2022 shares | Feb. 14, 2022 USD ($) $ / shares shares | May 12, 2017 USD ($) shares | Mar. 24, 2017 USD ($) $ / shares shares | Feb. 17, 2017 USD ($) $ / shares shares | Aug. 31, 2022 USD ($) shares | Mar. 31, 2022 USD ($) shares | Jul. 31, 2020 shares | Jul. 31, 2018 shares | Feb. 28, 2017 USD ($) | Dec. 31, 2023 USD ($) $ / shares shares | Dec. 31, 2022 USD ($) $ / shares shares | Dec. 31, 2021 USD ($) $ / shares shares | Feb. 28, 2021 $ / shares | Sep. 30, 2004 shares | |
Class of Warrant or Right, Exercised (in shares) | 0 | 515,000 | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price, Exercised (in dollars per share) | $ / shares | $ 0 | $ 0.12 | ||||||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 0 | 0 | 7,065,000 | |||||||||||||||||||
Preferred Stock, Shares Authorized (in shares) | 5,000,000 | |||||||||||||||||||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.01 | |||||||||||||||||||||
Share Price (in dollars per share) | $ / shares | $ 0.06 | $ 0.04 | $ 0.08 | 0.04 | $ 0.09 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0 | $ 0 | $ 0.11 | |||||||||||||||||||
Share-Based Payment Arrangement, Expense | $ | $ 464,041 | $ 352,458 | ||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value | $ | $ 16,000 | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares) | 0 | 1,200,000 | ||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 3,100,000 | 8,150,000 | ||||||||||||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares | $ 0.04 | $ 0.09 | ||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares | $ 0.05 | $ 0.07 | $ 0.06 | |||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares) | 1,000,000 | 3,306,000 | 1,734,000 | |||||||||||||||||||
Share-Based Payment Arrangement, Option [Member] | ||||||||||||||||||||||
Share-Based Payment Arrangement, Expense | $ | $ 199,554 | $ 280,393 | ||||||||||||||||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $ | $ 99,768 | |||||||||||||||||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 1 year 8 months 15 days | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value | $ | $ 442,295 | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum | 1.37% | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum | 4.14% | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0% | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum | 65.19% | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum | 70.09% | |||||||||||||||||||||
Share-Based Payment Arrangement, Option [Member] | Minimum [Member] | ||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year) | 5 years | |||||||||||||||||||||
Share-Based Payment Arrangement, Option [Member] | Maximum [Member] | ||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year) | 7 years 6 months | |||||||||||||||||||||
Qualified Options [Member] | ||||||||||||||||||||||
Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation (in shares) | 162,163 | 388,889 | ||||||||||||||||||||
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture (in shares) | 37,837 | 611,111 | ||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares) | 200,000 | 1,000,000 | 0 | |||||||||||||||||||
Share-Based Payment Arrangement, Expense, Tax Benefit | $ | $ 0 | $ 0 | ||||||||||||||||||||
Qualified Options [Member] | Share-Based Payment Arrangement, Employee [Member] | ||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 3,100,000 | 1,000,000 | ||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) | 5 years | 5 years | ||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) | 10 years | 10 years | ||||||||||||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares | $ 0.1 | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value | $ | $ 82,176 | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum | 3.94% | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum | 4.26% | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0% | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum | 68.65% | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum | 79.21% | |||||||||||||||||||||
Qualified Options [Member] | Share-Based Payment Arrangement, Employee [Member] | Share-Based Payment Arrangement, Tranche One [Member] | ||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) | 1 year | |||||||||||||||||||||
Qualified Options [Member] | Share-Based Payment Arrangement, Employee [Member] | Minimum [Member] | ||||||||||||||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares | $ 0.04 | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year) | 5 years | |||||||||||||||||||||
Qualified Options [Member] | Share-Based Payment Arrangement, Employee [Member] | Maximum [Member] | ||||||||||||||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares | $ 0.06 | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year) | 7 years | |||||||||||||||||||||
Restricted Stock Units (RSUs) [Member] | ||||||||||||||||||||||
Share-Based Payment Arrangement, Expense | $ | $ 121,202 | $ 0 | ||||||||||||||||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $ | $ 168,798 | |||||||||||||||||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 1 year 8 months 19 days | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) | 3 years | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares) | 750,000 | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 7,250,000 | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) | 250,000 | |||||||||||||||||||||
Chief Executive Officer [Member] | ||||||||||||||||||||||
Employment Agreement, Minimum Price Per share (in dollars per share) | $ / shares | $ 0.05 | |||||||||||||||||||||
One Employee [Member] | Qualified Options [Member] | Share-Based Payment Arrangement, Employee [Member] | ||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 25,000 | |||||||||||||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares | $ 0.08 | |||||||||||||||||||||
Two Employees [Member] | Qualified Options [Member] | Share-Based Payment Arrangement, Employee [Member] | ||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 125,000 | |||||||||||||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares | $ 0.03 | |||||||||||||||||||||
Executive Officer [Member] | Qualified Options [Member] | ||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 3,000,000 | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) | 10 years | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares | $ 0.09 | |||||||||||||||||||||
Executive Officer [Member] | Qualified Options [Member] | Share-Based Payment Arrangement, Tranche One [Member] | ||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 2,000,000 | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage | 50% | |||||||||||||||||||||
Executive Officer [Member] | Qualified Options [Member] | Share-Based Payment Arrangement, Tranche Two [Member] | ||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) | 1 year | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage | 50% | |||||||||||||||||||||
Director [Member] | Non-qualified Options [Member] | ||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 4,000,000 | |||||||||||||||||||||
Executive Officers and Directors [Member] | Qualified Options [Member] | Share-Based Payment Arrangement, Tranche One [Member] | ||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage | 25% | |||||||||||||||||||||
Executive Officers and Directors [Member] | Qualified Options [Member] | Share-Based Payment Arrangement, Tranche Two [Member] | ||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage | 25% | |||||||||||||||||||||
President [Member] | Restricted Stock Units (RSUs) [Member] | ||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) | 2,500,000 | |||||||||||||||||||||
Share-Based Payment Arrangement, Expense | $ | $ 150,000 | |||||||||||||||||||||
Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation (in shares) | 778,972 | |||||||||||||||||||||
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture (in shares) | 1,721,028 | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 6,500,000 | |||||||||||||||||||||
President [Member] | Restricted Stock Units (RSUs) [Member] | Share-Based Payment Arrangement, Tranche One [Member] | ||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) | 1,500,000 | |||||||||||||||||||||
President [Member] | Restricted Stock Units (RSUs) [Member] | Share-Based Payment Arrangement, Tranche Two [Member] | ||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) | 2,000,000 | |||||||||||||||||||||
President [Member] | Restricted Stock Units (RSUs) [Member] | Share-Based Payment Arrangement, Tranche Three [Member] | ||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) | 3,000,000 | |||||||||||||||||||||
Employee Stock Purchase Plan [Member] | ||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) | 2,000,000 | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Percent of Gross Pay | 15% | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) | 3,000,000 | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) | 2,224,544 | |||||||||||||||||||||
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares) | 316,866 | 245,081 | ||||||||||||||||||||
Stock Issued During Period, Value, Employee Stock Purchase Plan | $ | $ 8,398 | $ 14,771 | ||||||||||||||||||||
The 2015 Incentive Plan [Member] | ||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) | 80,000,000 | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) | 20,000,000 | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) | 20,292,546 | |||||||||||||||||||||
The 2015 Incentive Plan [Member] | Chief Executive Officer [Member] | ||||||||||||||||||||||
Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture (in shares) | 560,000 | 307,692 | ||||||||||||||||||||
Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture | $ | $ 28,000 | $ 28,000 | ||||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 0.05 | $ 0.091 | ||||||||||||||||||||
Employment Agreement, Minimum Price Per share (in dollars per share) | $ / shares | $ 0.05 | |||||||||||||||||||||
Share-Based Payment Arrangement, Expense | $ | $ 22,400 | $ 27,692 | ||||||||||||||||||||
Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation (in shares) | 216,440 | 120,461 | ||||||||||||||||||||
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture (in shares) | 343,560 | 187,231 | ||||||||||||||||||||
The 2006 Plan [Member] | ||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) | 11,089,967 | |||||||||||||||||||||
Conversion of Convertible Debentures Into Series C Preferred Stock and Warrants [Member] | ||||||||||||||||||||||
Preferred Stock, Shares Outstanding (in shares) | 630 | 630 | ||||||||||||||||||||
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 1,000 | |||||||||||||||||||||
Proceeds from Issuance of Preferred Stock and Preference Stock | $ | $ 675,947 | |||||||||||||||||||||
Preferred Stock, Discount on Shares | $ | $ 0 | $ 4,737 | ||||||||||||||||||||
Preferred Stock, Value, Issued | $ | $ 630,000 | $ 625,263 | ||||||||||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued (in shares) | 2,925,000 | 3,750 | ||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ | $ 780,000 | $ 205,000 | ||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | 780 | |||||||||||||||||||||
Convertible Debt [Member] | ||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8% | |||||||||||||||||||||
Repayments of Convertible Debt | $ | $ 1,835,000 | |||||||||||||||||||||
Subscription Agreements with Certain Investors [Member] | ||||||||||||||||||||||
Proceeds from Issuance or Sale of Equity | $ | $ 3,433,000 | |||||||||||||||||||||
Conversion of Series B Preferred Stock Into Common Stock [Member] | ||||||||||||||||||||||
Preferred Stock, Redemption Price Per Share (in dollars per share) | $ / shares | $ 1,000 | |||||||||||||||||||||
Conversion of Stock, Shares Converted (in shares) | 675 | 175 | ||||||||||||||||||||
Conversion of Stock, Amount Issued | $ | $ 675,000 | |||||||||||||||||||||
Conversion of Stock, Shares Issued (in shares) | 8,437,500 | |||||||||||||||||||||
Conversion of Series C Preferred Stock Into Common Stock [Member] | ||||||||||||||||||||||
Conversion of Stock, Shares Converted (in shares) | 150 | |||||||||||||||||||||
Series B Preferred Stock [Member] | ||||||||||||||||||||||
Preferred Stock, Shares Outstanding (in shares) | 675 | |||||||||||||||||||||
Preferred Stock, Redemption Price Per Share (in dollars per share) | $ / shares | $ 1,000 | |||||||||||||||||||||
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount | $ | $ 675,000 | |||||||||||||||||||||
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 2 | |||||||||||||||||||||
Preferred Stock, Dividend Rate, Percentage | 0% | |||||||||||||||||||||
Series C Preferred Stock [Member] | ||||||||||||||||||||||
Preferred Stock, Shares Outstanding (in shares) | 4,063 | 4,063 | ||||||||||||||||||||
Preferred Stock, Redemption Price Per Share (in dollars per share) | $ / shares | $ 1,000 | |||||||||||||||||||||
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 0.1 | |||||||||||||||||||||
Preferred Stock, Convertible, Threshold Trading Days | 90 | |||||||||||||||||||||
Preferred Stock, Convertible, Stock Price Trigger (in dollars per share) | $ / shares | $ 0.25 | |||||||||||||||||||||
Dividends Payable | $ | $ 243,780 | $ 243,780 | ||||||||||||||||||||
Stock Dividends, Shares (in shares) | 2,266,500 | 2,271,980 | ||||||||||||||||||||
Dividends, Preferred Stock | $ | $ 90,660 | $ 204,480 | ||||||||||||||||||||
Payments of Dividends | $ | $ 153,120 | $ 39,300 | ||||||||||||||||||||
Series C Preferred Stock [Member] | Subscription Agreements with Certain Investors [Member] | ||||||||||||||||||||||
Preferred Stock, Shares Outstanding (in shares) | 3,433 | |||||||||||||||||||||
Preferred Stock, Dividend Rate, Percentage | 6% | |||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 3,433 | |||||||||||||||||||||
Proceeds from Issuance of Preferred Stock and Preference Stock | $ | $ 2,895,379 | |||||||||||||||||||||
Preferred Stock, Discount on Shares | $ | 13,440 | $ 0 | ||||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ | $ 3,419,560 | |||||||||||||||||||||
Preferred Stock, Value, Issued | $ | $ 3,433,000 | |||||||||||||||||||||
Class M Warrants [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Exercised (in shares) | 515,000 | |||||||||||||||||||||
Class of Warrant or Right, Exercise Price, Exercised (in dollars per share) | $ / shares | $ 0.12 | |||||||||||||||||||||
Proceeds from Warrant Exercises | $ | $ 61,800 | |||||||||||||||||||||
Class of Warrants or Rights, Expirations (in shares) | 3,625,000 | |||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 17,165,000 | |||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.12 | |||||||||||||||||||||
Proceeds from Issuance of Warrants | $ | $ 537,621 | |||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||||||||
Class N Warrants [Member] | ||||||||||||||||||||||
Class of Warrants or Rights, Expirations (in shares) | 2,925,000 | |||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.1 | |||||||||||||||||||||
Proceeds from Issuance of Warrants | $ | $ 104,053 | |||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years |
Note 9 - Shareholders' Equity_4
Note 9 - Shareholders' Equity, Redeemable Convertible Preferred Stock, Options and Warrants - Schedule of Warrant Activity (Details) - $ / shares | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Outstanding, warrants (in shares) | 0 | 7,065,000 |
Outstanding, warrants, weighted average exercise price (in dollars per share) | $ 0 | $ 0.11 |
Granted, warrants (in shares) | 0 | 0 |
Granted, warrants, weighted average exercise price (in dollars per share) | $ 0 | $ 0 |
Exercised, warrants (in shares) | 0 | (515,000) |
Exercised, warrants, weighted average exercise price (in dollars per share) | $ 0 | $ 0.12 |
Forfeited, warrants (in shares) | 0 | (6,550,000) |
Forfeited, warrants, weighted average exercise price (in dollars per share) | $ 0 | $ 0.11 |
Outstanding, warrants (in shares) | 0 | 0 |
Outstanding, warrants, weighted average exercise price (in dollars per share) | $ 0 | $ 0 |
Note 9 - Shareholders' Equity_5
Note 9 - Shareholders' Equity, Redeemable Convertible Preferred Stock, Options and Warrants - Option Activity (Details) - USD ($) | 12 Months Ended | |||
Mar. 03, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Outstanding (in shares) | 24,993,500 | 20,777,500 | ||
Outstanding, weighted average exercise price (in dollars per share) | $ 0.07 | $ 0.06 | ||
Outstanding, aggregate intrinsic value | $ 17,000 | $ 0 | $ 627,615 | |
Granted (in shares) | 3,100,000 | 8,150,000 | ||
Granted, weighted average exercise price (in dollars per share) | $ 0.04 | $ 0.09 | ||
Exercised (in shares) | 0 | (1,200,000) | ||
Exercised, weighted average exercise price (in dollars per share) | $ 0.04 | |||
Exercised, aggregate intrinsic value | $ 57,000 | |||
Forfeited (in shares) | (1,000,000) | (3,306,000) | (1,734,000) | |
Forfeited, weighted average exercise price (in dollars per share) | $ 0.08 | $ 0.08 | ||
Outstanding (in shares) | 24,787,500 | 24,993,500 | ||
Outstanding, weighted average exercise price (in dollars per share) | $ 0.05 | $ 0.07 | ||
Outstanding, weighted average remaining contractual life (Year) | 5 years 4 months 24 days | |||
Exercisable (in shares) | 19,372,500 | |||
Exercisable, weighted average exercise price (in dollars per share) | $ 0.05 | |||
Exercisable, weighted average remaining contractual life (Year) | 4 years 7 months 6 days | |||
Exercisable, aggregate intrinsic value | $ 16,000 |
Note 9 - Shareholders' Equity_6
Note 9 - Shareholders' Equity, Redeemable Convertible Preferred Stock, Options and Warrants - Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Outstanding, number (in shares) | |||
Outstanding, weighted average grant date fair value (in dollars per share) | |||
Granted, number (in shares) | 7,250,000 | ||
Granted, weighted average grant date fair value (in dollars per share) | $ 0.04 | ||
Exercised, number (in shares) | (250,000) | ||
Exercised, weighted average grant date fair value (in dollars per share) | $ 0.04 | ||
Forfeited, number (in shares) | |||
Forfeited, weighted average grant date fair value (in dollars per share) | |||
Outstanding, number (in shares) | 7,000,000 | ||
Outstanding, weighted average grant date fair value (in dollars per share) |
Note 10 - Income Taxes (Details
Note 10 - Income Taxes (Details Textual) - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Income Tax Expense (Benefit) | $ 0 | $ 0 |
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 21% | |
Operating Loss Carryforwards | $ 37,000,000 | |
Unrecognized Tax Benefits | 0 | |
Unrecognized Tax Benefits, Period Increase (Decrease) | 0 | |
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense | $ 0 |
Note 10 - Income Taxes - Schedu
Note 10 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Income tax expense (benefit) | $ (182,493) | $ 72,207 |
Book and tax differences | 40,577 | (72,207) |
State taxes net of federal benefit | 0 | 0 |
Change in valuation allowance | $ 141,916 | $ 0 |
Note 10 - Income Taxes - Sche_2
Note 10 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
Net operating loss carryforward | $ 7,918,996 | $ 7,736,618 |
Valuation allowance | (7,476,180) | (7,363,815) |
Total deferred income tax asset | 442,816 | 372,803 |
Deferred income tax liability - depreciation | (442,816) | (372,803) |
Deferred tax asset (liability) | $ 0 | $ 0 |
Note 11 - Commitments and Con_2
Note 11 - Commitments and Contingencies (Details Textual) | 12 Months Ended | |||
Oct. 02, 2014 | Aug. 31, 2011 USD ($) | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | |
The 401K Plan [Member] | ||||
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount | $ 23,000 | |||
Defined Contribution Plan, Cost | $ 0 | |||
Land in Lea County, New Mexico [Member] | ||||
Number of Employees Hired | 75 | |||
Property, Plant, and Equipment, Fair Value Disclosure | $ 776,078 | |||
Asset Purchase, Interest | 5.25% | |||
Asset Pledged as Collateral [Member] | Surety Bond [Member] | ||||
Money Market Funds, at Carrying Value | $ 880,752 | $ 840,049 | ||
Contract With the DOE for the Irradiation of Cobalt Targets [Member] | ||||
Contract Term (Year) | 10 years | |||
Other Commitments, Annual Fixed Price, Escalation Percent | 5% | |||
Customer Concentration Risk [Member] | Revenue from Contract with Customer Benchmark [Member] | ||||
Number of Major Customers | 3 | |||
Customer Concentration Risk [Member] | Revenue from Contract with Customer Benchmark [Member] | Three Customers [Member] | ||||
Concentration Risk, Percentage | 22% |
Note 12 - Asset Retirement Ob_3
Note 12 - Asset Retirement Obligation - Schedule of Asset Retirement Obligation Activity (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Balance | $ 942,378 | $ 892,087 |
Increase in lease disposal costs | 478,959 | 0 |
Accretion expense/amortization expense | 53,126 | 50,291 |
Balance | $ 1,474,463 | $ 942,378 |
Note 13 - Fair Value Measurem_2
Note 13 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Estimate of Fair Value Measurement [Member] | ||
Assets, Fair Value Disclosure | $ 0 | $ 0 |
Note 14 - Revenue Recognition_2
Note 14 - Revenue Recognition (Details Textual) - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
Deferred Revenue, Current | $ 932,682 | $ 879,365 |
Accounts Receivable, after Allowance for Credit Loss, Current | $ 1,469,298 | $ 1,596,886 |
Note 14 - Revenue Recognition -
Note 14 - Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Sale of product | $ 12,267,385 | $ 11,181,988 |
Percent of total revenues | 100% | 100% |
Theranostics Products [Member] | ||
Sale of product | $ 6,842,898 | $ 6,045,767 |
Percent of total revenues | 56% | 54% |
Cobalt Products [Member] | ||
Sale of product | $ 1,037,073 | $ 1,157,536 |
Percent of total revenues | 8% | 10% |
Nuclear Medicine Products [Member] | ||
Sale of product | $ 4,387,414 | $ 3,978,685 |
Percent of total revenues | 36% | 36% |
Fluorine Products [Member] | ||
Sale of product | $ 0 | $ 0 |
Percent of total revenues | 0% | 0% |
UNITED STATES | ||
Sale of product | $ 10,023,667 | $ 9,648,831 |
UNITED STATES | Theranostics Products [Member] | ||
Sale of product | 5,685,244 | 5,338,010 |
UNITED STATES | Cobalt Products [Member] | ||
Sale of product | 932,915 | 1,137,066 |
UNITED STATES | Nuclear Medicine Products [Member] | ||
Sale of product | 3,405,508 | 3,173,755 |
UNITED STATES | Fluorine Products [Member] | ||
Sale of product | 0 | 0 |
Non-US [Member] | ||
Sale of product | 2,243,718 | 1,533,157 |
Non-US [Member] | Theranostics Products [Member] | ||
Sale of product | 1,157,654 | 707,757 |
Non-US [Member] | Cobalt Products [Member] | ||
Sale of product | 104,158 | 20,470 |
Non-US [Member] | Nuclear Medicine Products [Member] | ||
Sale of product | 981,906 | 804,930 |
Non-US [Member] | Fluorine Products [Member] | ||
Sale of product | $ 0 | $ 0 |
Note 15 - Segment Information -
Note 15 - Segment Information - Schedule of Segment Information by Segment (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Sale of product | $ 12,267,385 | $ 11,181,988 |
Depreciation and amortization | 350,094 | 374,196 |
Net income (loss) | (869,016) | 303,238 |
Expenditures for segment assets | 149,058 | 120,014 |
Segment assets | 16,905,087 | 16,244,596 |
Theranostics Products [Member] | ||
Sale of product | 6,842,898 | 6,045,767 |
Cobalt Products [Member] | ||
Sale of product | 1,037,073 | 1,157,536 |
Nuclear Medicine Products [Member] | ||
Sale of product | 4,387,414 | 3,978,685 |
Fluorine Products [Member] | ||
Sale of product | 0 | 0 |
Operating Segments [Member] | ||
Sale of product | 12,267,385 | 11,181,988 |
Depreciation and amortization | 309,330 | 343,283 |
Net income (loss) | 3,192,364 | 3,985,735 |
Expenditures for segment assets | 88,331 | 100,062 |
Segment assets | 9,642,540 | 9,373,600 |
Operating Segments [Member] | Theranostics Products [Member] | ||
Sale of product | 6,842,898 | 6,045,767 |
Depreciation and amortization | 25,287 | 63,493 |
Net income (loss) | 3,037,375 | 4,182,151 |
Expenditures for segment assets | 3,420 | 3,379 |
Segment assets | 849,351 | 1,075,252 |
Operating Segments [Member] | Cobalt Products [Member] | ||
Sale of product | 1,037,073 | 1,157,536 |
Depreciation and amortization | 53,331 | 49,202 |
Net income (loss) | (126,504) | (95,779) |
Expenditures for segment assets | 49,774 | 17,105 |
Segment assets | 274,513 | 406,629 |
Operating Segments [Member] | Nuclear Medicine Products [Member] | ||
Sale of product | 4,387,414 | 3,978,685 |
Depreciation and amortization | 114,833 | 114,990 |
Net income (loss) | 386,592 | 39,223 |
Expenditures for segment assets | 35,137 | 75,478 |
Segment assets | 3,538,558 | 2,744,394 |
Operating Segments [Member] | Fluorine Products [Member] | ||
Sale of product | 0 | 0 |
Depreciation and amortization | 115,879 | 115,598 |
Net income (loss) | (105,099) | (139,860) |
Expenditures for segment assets | 0 | 4,100 |
Segment assets | 4,980,118 | 5,147,325 |
Corporate, Non-Segment [Member] | ||
Sale of product | 0 | 0 |
Depreciation and amortization | 40,764 | 30,913 |
Net income (loss) | (4,061,380) | (3,682,497) |
Expenditures for segment assets | 60,727 | 19,952 |
Segment assets | $ 7,262,547 | $ 6,870,996 |
Note 16 - Subsequent Events (De
Note 16 - Subsequent Events (Details Textual) - Subsequent Event [Member] - Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | Feb. 08, 2024 USD ($) |
Prepayment for DUF Plant [Member] | |
Proceeds from Sale of Productive Assets | $ 50,000 |
DUF Plant [Member] | |
Proceeds from Sale of Productive Assets | $ 12,500,000 |